Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CG 009301

Next Previous
Drug Profile

CG 009301

Latest Information Update: 14 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cullgen
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Peptide-chain-release factor 3 degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 04 May 2026 Cullgen has been acquired by Gyre Therapeutics
  • 17 Apr 2025 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater, Recurrent) in China (IV, Injection) (NCT07347171) (Cullgen pipeline, July 2025)
  • 13 Nov 2024 Cullgen plans a phase I trial for Hematological malignancies in China in Q1 of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top